MedTrace Logo

Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma

NCT00003647 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2008-07-25

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Injecting allovectin-7 into a person's melanoma cells may make the body build an immune response that will kill tumor cells.

PURPOSE: Randomized phase III trial to compare the effectiveness of dacarbazine with or without immunotherapy in treating patients who have stage III or stage IV melanoma.

Conditions

  • Stage IV Melanoma
  • Stage III Melanoma
  • Recurrent Melanoma

Interventions

DRUG

allovectin-7

DRUG

allovectin-7/dacarbazine

DRUG

dacarbazine

Sponsors & Collaborators

  • Vical

    lead INDUSTRY

Principal Investigators

  • Cherie Smith · Vical

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-07-31
Completion
2002-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003647 on ClinicalTrials.gov